Regentis Biomaterials Nears Key Milestones for Simplified Cartilage Repair Implant
Regentis Biomaterials advances GelrinC, a single-step hydrogel implant for knee cartilage repair, targeting a $3 billion U.S. market with CE Mark approval and a Phase III trial over 50% enrolled.
Regentis Biomaterials Ltd. (NYSE American: RGNT) is progressing toward key commercial milestones for GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair. The device is intended to offer an alternative to traditional microfracture and complex cell-based therapies through a single-step, approximately 10-minute procedure. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists.
Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled, positioning Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.
The Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC® is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. For a full corporate profile, visit https://ibn.fm/bpPp6.
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, the company’s lead product aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available.
Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company's SEC filings. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer.